In 2020, retinal and optic nerve diseases such as age-related macular degeneration, glaucoma and diabetic retinopathy remained the leading causes of irreversible blindness or visual impairment in >20 million people worldwide (Lancet Glob Health 2021; 9: e489–551). Along with other posterior eye diseases, there remain similar challenges in their diagnosis, prediction of disease onset or progression, and understanding of the disease mechanisms. These challenges remain significant barriers in the prevention of vision loss in eye care and in the discovery of new therapeutics. However, recent advances in artificial intelligence show promise in tackling many of these challenges, especially through exploiting the increasing ubiquity and resolution of retinal imaging.
This Research Topic thus aims to include studies that specifically explore how artificial intelligence has been applied to overcome current barriers in preventing vision loss from retinal and optic nerve diseases.
We specifically invite original articles examining research questions with a clear clinical translational goal in view. Studies may include those evaluating, but not limited to:
- Application of artificial intelligence in the early diagnosis of retinal or optic nerve diseases
- Applications in the prediction of disease progression
- Characterization of biomarkers or pathological features that will aid in the understanding of novel disease pathways
We also invite critical reviews of how artificial intelligence is, or could be, applied to prevent vision loss in retinal and optic nerve diseases.
Topic Editor FM declares that they have consultancies with: Aeri Pharmaceuticals; Allergan, Annexon, Carl Zeiss Meditec, Galimedix, Stealth Biotherapeutics, Stuart Therapeutics, Reichert. Topic Editor LMZ declares that they are a consultant for Abbvie Inc. All other Editors declare no conflicts of interest.
In 2020, retinal and optic nerve diseases such as age-related macular degeneration, glaucoma and diabetic retinopathy remained the leading causes of irreversible blindness or visual impairment in >20 million people worldwide (Lancet Glob Health 2021; 9: e489–551). Along with other posterior eye diseases, there remain similar challenges in their diagnosis, prediction of disease onset or progression, and understanding of the disease mechanisms. These challenges remain significant barriers in the prevention of vision loss in eye care and in the discovery of new therapeutics. However, recent advances in artificial intelligence show promise in tackling many of these challenges, especially through exploiting the increasing ubiquity and resolution of retinal imaging.
This Research Topic thus aims to include studies that specifically explore how artificial intelligence has been applied to overcome current barriers in preventing vision loss from retinal and optic nerve diseases.
We specifically invite original articles examining research questions with a clear clinical translational goal in view. Studies may include those evaluating, but not limited to:
- Application of artificial intelligence in the early diagnosis of retinal or optic nerve diseases
- Applications in the prediction of disease progression
- Characterization of biomarkers or pathological features that will aid in the understanding of novel disease pathways
We also invite critical reviews of how artificial intelligence is, or could be, applied to prevent vision loss in retinal and optic nerve diseases.
Topic Editor FM declares that they have consultancies with: Aeri Pharmaceuticals; Allergan, Annexon, Carl Zeiss Meditec, Galimedix, Stealth Biotherapeutics, Stuart Therapeutics, Reichert. Topic Editor LMZ declares that they are a consultant for Abbvie Inc. All other Editors declare no conflicts of interest.
